TBK1 and non-alcoholic fatty liver: Recent studies have shown that ALX, as a specific inhibitor of TANK-binding kinase 1(TBK1)/IkB kinase ε (IKKε), can suppress chronic inflammation in type II diabetes [3], non-alcoholic fatty liver [4], and obesity-related metabolic dysfunction [5].